It is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...

Eli Lilly launches diabetes and obesity drug Mounjaro in India, offering innovative treatment for metabolic health management ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain Both the injectable and oral ...

The new class of weight-loss medicines that has taken the world by a storm will now become available in India, with the ...

Danish drugmaker Novo Nordisk’s injectable semaglutide – sold under brand names Ozempic and Wegovy –may also be launched in India sometime this year. The innovator hasn’t clarified a ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

[i] Rybelsus (semaglutide) tablets are FDA-approved for oral use and were not in shortage. The FDA’s February Declaratory order specifically addresses the compounding of semaglutide injection ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...